| Literature DB >> 33215311 |
Qiuqin Zhou1, Annabelle Fülöp1, Carsten Hopf2.
Abstract
Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) is a fast-growing technique for visualization of the spatial distribution of the small molecular and macromolecular biomolecules in tissue sections. Challenges in MALDI-MSI, such as poor sensitivity for some classes of molecules or limited specificity, for instance resulting from the presence of isobaric molecules or limited resolving power of the instrument, have encouraged the MSI scientific community to improve MALDI-MSI sample preparation workflows with innovations in chemistry. Recent developments of novel small organic MALDI matrices play a part in the improvement of image quality and the expansion of the application areas of MALDI-MSI. This includes rationally designed/synthesized as well as commercially available small organic molecules whose superior matrix properties in comparison with common matrices have only recently been discovered. Furthermore, on-tissue chemical derivatization (OTCD) processes get more focused attention, because of their advantages for localization of poorly ionizable metabolites and their' in several cases' more specific imaging of metabolites in tissue sections. This review will provide an overview about the latest developments of novel small organic matrices and on-tissue chemical derivatization reagents for MALDI-MSI. Graphical abstract.Entities:
Keywords: MALDI imaging; MALDI matrix; MALDI-MSI; On-tissue chemical derivatization; Tissue preparation
Mesh:
Substances:
Year: 2020 PMID: 33215311 PMCID: PMC8007514 DOI: 10.1007/s00216-020-03023-7
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.142
Fig. 1Schema of experimental workflow for MALDI-MSI with highlighted important steps for tissue preparation
Fig. 2Structures of selected novel MALDI matrices for imaging
Rationally designed novel matrices and newly discovered novel matrices for MALDI-MSI
| Matrix abbr. | Matrix | Target analyte classes | Ion modes | Properties | Deposition | Ref. |
|---|---|---|---|---|---|---|
| • Rationally designed small organic substances as novel matrices | ||||||
| 2,5-cDHA | (E)-4-(2,5-dihydroxyphenyl)but-3-en-2-one | Protein, lipid | +, − * | More vacuum-stable, small crystals for higher spatial resolution, improved sensitivity, dual-polarity for lipids | Two-step spraying | [ |
| COOH-NHMe | 2-(Methylamino)benzoic acid | Lipid, protein | +, − | Dual-polarity, detection of more lipid and protein species | Sublimation | [ |
| • Newly discovered small organic substances as novel matrices | ||||||
| PNA | N-Phenyl-2-naphthylamine | FA, AA, antioxidant, lipid | – | Strong UV-absorption, low matrix background signals, salt tolerance capacity | Spraying | [ |
| NEDC | N-(1-Naphthyl)ethylenediamine dihydrochloride | Glucose, Na+, K+, AA, nucleotide, antioxidant, glycerophospholipid | – | Salt tolerance capacity, low matrix background signals, improved sensitivity for selected analyte classes | Spraying | [ |
| 3-APH | 3-Aminophthalhydrazide | Nucleotide, FA, lipid | +, − | Dual-polarity, improved sensitivity, broad molecular coverage, low matrix background signals, vacuum stability | Spraying | [ |
| IR-780 | (Poly)phosphoinositide, cardiolipin, ganglioside | – | Proton affinity, vacuum stability, homogenous crystals, salt tolerance capacity | Spraying | [ | |
| DPH | 1,6-Diphenyl-1,3,5-hexatriene | Lipid, FA with polyene structure | – | Vacuum stability, high spatial resolution | Sublimation | [ |
| BNDM | 1,1′-Binaphthyl-2,2′-diamine | AA, organic acid, nucleoside, nucleotide, nitrogenous base, cholesterol, peptide, FA, choline, carnitine, polyamine, creatine, lipid | +, − | Low matrix background signals, improved sensitivity, dual-polarity, broad molecular coverage | Spraying | [ |
| DCH | 2,3-Dicyanohydroquinone | Lipid | + | High spatial resolution, vacuum stability, chemical stability, sensitivity | Spraying | [ |
| DCTB | (2-[(2E)-3-(4-Tert-butylphenyl)-2-methylprop-2-enylidene]malononitrile) | Central nervous system drug | + | Improved sensitivity, low signal suppression | Spraying | [ |
| DMCA | 3,4-Dimethoxycinnamic acid | Small molecule | + | Low matrix background signals, sensitivity, broad molecular coverage | Spraying | [ |
*Positive ion mode for protein and dual-polarity for lipid. AA amino acid, FA fatty acid
MALDI-MSI approaches with on-tissue chemical derivatization of analytes in tissue sections
| Target analytes in tissue sections | OTCD reagent | Solution | Application and incubation | Tissue | Ref. |
|---|---|---|---|---|---|
| Amine as targeted functional groups | |||||
| Isoniazid | CA | 50% in MeOH | High velocity spin coating, 30 min at RT | Lung tissue sections of rabbit infected with | [ |
| Dopamine, norepinephrine, epinephrine, γ-aminobutyric acid | CA | 23 mg/mL CA and 8.5 mg/mL | Automatic spraying | Adrenal gland tissue sections of pig, brain tissue sections of rat | [ |
| Glycine, alanine, serine, proline, valine, threonine, isoleucine/leucine, aspartate, glutamine, lysine, glutamate, tryptophan, dopamine, γ-aminobutyric acid, taurine, 3-methoxytyramine, serotonin, L-dihydroxyphenylalanine | CA | 4 mg/mL in 50% MeOH | Automatic spraying, overnight at RT | Brain tissue sections from female C57BL/6J mice | [ |
| Glycine, alanine, aminobutenoic acid, serine, γ-aminobutyric acid and more other metabolites | CA | 20 mg/mL in MeOH | Electrospraying | Leaf and root tissue sections of two different maize genotypes (B73 and Mo17) | [ |
| 67 small-molecule metabolites including amino acids, neurotransmitters, dipeptides and others | CA | 5 mg/mL in 50% MeOH | Electrospraying, overnight at 37 °C | Brain tissue sections of rats | [ |
| Neuropeptides | NBA + hv | 5 mg/mL in ACN/EtOH/FA/H2O | Automatic spraying, nanosecond with | Brain tissue sections from mouse brain | [ |
| Amino acids excluding lysine, serine, histidine, threonine, aspartate and arginine | TAHS | 5 mg/mL in ACN | Airbrush, overnight at 55 °C | Liver tissue sections from xenograft mouse models of human colon cancer | [ |
| Glycine, alanine, serine, proline, valine, threonine, isoleucine/leucine, aspartate, glutamine, lysine, glutamate, tryptophan, dopamine, γ-aminobutyric acid, taurine, 3-methoxytyramine, serotonin, L-dihydroxyphenylalanine | TAHS | 5 mg/mL in 50% ACN | Automatic spraying, overnight at RT | Brain tissue sections from female C57BL/6 J mice | [ |
| Phenylalanine, tyrosine | TAHS | 5 mg/mL in ACN | Automatic spraying, 24 h at 55 °C | Liver tissue sections from a H460 human NSCLC xenograft mouse model | [ |
| Noradrenaline | TAHS | 5 mg/mL in ACN | Airbrush, 15 min at 55 °C | Adrenal gland tissue sections from tumor patients | [ |
| Glutamine | TAHS | 5 mg/mL in ACN | Automatic spraying, 24 h at 55 °C | Tumor and benign tissue sections from tumor patients | [ |
| Dopamine, tyrosine, tryptamine, tyramine, phenethylamine, 3-methoxytyramine, serotonin, γ-aminobutyric acid, glutamate | DPP-TFB**, TMP-TFB | 0.09 mg/mL in 50% MeOH with 0.06% TEA | Automatic spraying, 30 min at RT | Brain tissue sections from treated and control male Sprague-Dawley rats and C57BL/6J male mice, brain tissue sections from primate | [ |
| Dopamine and amphetamine, β-N-methylamino-L-alanine | DPP*, TMP, PBDPP* | 1.11 mg/mL in 75% MeOH with 0.05% TEA, 1 mg/mL in 83% MeOH with 0.05% TEA, 0.2 mg/mL in 80% MeOH with 0.07% TEA | Automatic spraying, 15 min at RT | Brain tissue sections from the treated and untreated C57BL/6J male mice, male Wistar rat pups or adult Sprague-Dawley rats | [ |
| Glycine, alanine, serine, proline, valine, threonine, isoleucine/leucine, aspartate, glutamine, lysine, glutamate, tryptophan, dopamine, γ-aminobutyric acid, taurine, 3-methoxytyramine, serotonin, L-dihydroxyphenylalanine | DPP-TFB | 5 mg/mL in MeOH | Automatic spraying, overnight at RT | Brain tissue sections from female C57BL/6J mice | [ |
| Glutamate, γ-aminobutyric acid | DPP-TFB | 1.33 mg/mL in MeOH | Manual spraying, direct spraying of matrix | Brain tissue sections from SCR-KO and WT mice | [ |
| Dopamine, serotonin, norepinephrine | DPP-TFB | 1.3 mg/mL in MeOH | Airbrush, direct spraying of matrix | Whole brain of the C57BL/6J mouse | [ |
| Dopamine, 3-methoxytyramine | DPP-TFB | 1.3 mg/mL in MeOH | Airbrush, direct spraying of matrix | Brain tissue sections from male C57BL/6J mice and WT mice | [ |
| Dopamine, glycine, alanine, γ-aminobutyric acid, proline, valine, threonine, taurine, leucine, aspartate, tyramine, glutamine, lysine, glutamate, tryptamine, 3-methoxytyramine, tyrosine, L-dihydroxyphenylalanine | DPP-TFB | 5 mg/mL in MeOH | Automatic spraying, overnight | Brain tissue sections from glioblastoma multiforme mice and WT mice | [ |
| Dopamine, serotonin, γ-aminobutyric acid, histamine, threonine, phenethylamine, methylhistamine, agmatine, adenine, tyramine, lysine, tryptamine, L-dihydroxyphenylalanine | DPP-TFB | 1.33 mg/mL in 75% MeOH with 0.05% TEA | Automatic spraying, 24 h at RT | Brain tissue sections from rock crabs | [ |
| Dopaminergic and serotonergic neurotransmitters and their associated metabolites containing primary and secondary amine groups | FMP-8*, FMP-9*, FMP-10* | 4.4 mM in 70% ACN | Automatic spraying, no incubation | Brain tissue sections from treated and untreated rat and primate models of Parkinsonism, brain tissue sections from a patient with Parkinson’s disease | [ |
| Dopamine, γ-aminobutyric acid | FMP-10* | 1.8 mg/mL in 70% ACN | Automatic spraying, no incubation | Brain tissue sections from GPR37 KO mice and WT mice | [ |
| Phenolic hydroxyl as targeted functional groups | |||||
| Cannabinoids and their metabolites | FMPTS | 10 mg/mL in ACN | Airbrush | Human hair | [ |
| Catecholamines (dopamine, epinephrine, norepinephrine) | (N-Me)Py+B(OH)2* | 12 mg/mL in 60% ACN | Automatic spraying | Adrenal gland tissue sections from pig | [ |
| Dopaminergic and serotonergic neurotransmitters and their associated metabolites containing phenolic hydroxyl groups | FMP-8*, FMP-9*, FMP-10* | 4.4 mM in 70% ACN | Automatic spraying, no incubation | Brain tissue sections from treated and untreated rats and primate models of Parkinsonism, brain tissue sections from a patient with Parkinson’s disease | [ |
| Carbonyl as targeted functional groups | |||||
| Fluticasone propionate | DMNTH*, DNPH* | 5 mg/mL in 50% ACN with 0.1% TFA, 4 mg/mL in 50% ACN | Spotting, 48 h at 37 °C | Rat lung tissue sections | [ |
| 11-Dehydrocorticosterone and corticosterone | GirT | 0.15 mg/cm2, addition spraying of MeOH with 0.2% TFA | Precoated, 60 min at 40 °C | Adrenal gland tissue sections of Sprague-Dawley rat and brain tissue sections of C57BL/6 mice | [ |
| Triamcinolone acetonide | GirT | 5 mg/mL in MeOH with 0.2% TFA | Automatic spraying, 150 min at 40 °C | Human incubated cartilage | [ |
| Testosterone | GirT | 5 mg/mL in 2.5% acetic acid | Airbrush, 90 min at RT | Testis tissue sections of C57BL/6 mice after human chorionic gonadotrophin treatment | [ |
| Testosterone and 5α-dihydrotestosterone | GirT | 5 mg/mL in 80% MeOH with 0.1% TFA | Automatic spraying, 60 min at 40 °C | Testis tissue sections of C57BL/6 mice and prostate tissue sections of Sprague-Dawley rats after human chorionic gonadotrophin treatment | [ |
| Cortisone, aldosterone, 18-oxocortisol and progesterone | GirT | 10 mg/mL in 20% acetic acid | Airbrush, 90 min at RT | Adrenal gland tissue sections of human patients and Sprague Dawley rats | [ |
| Abscisic acid and 12-oxo-phytodienoic acid | GirT | 5 mg/mL in 80% MeOH with 2% TFA | Airbrush, 30 min at RT | Immature | [ |
| Pyruvic acid, glycolaldehyde, 2-pentenal, dithylacetone, 1-hexanal, 1-heptanal, jasmonic acid, dotriacontanal and more other metabolites | GirT | 10 mg/mL in MeOH with 2% TFA | Electrospraying | Leaf and root tissue sections of two different maize genotypes (B73 and Mo17) | [ |
| 11-Dehydrocorticosterone, corticosterone | GirT | 5 mg/mL in 80% MeOH with 0.2% TFA | Electrospraying, 1 h at 40 °C | Brain tissue sections of Sprague-Dawley rats | [ |
| Aldosterone, cortisol, cortisone, 18-OH-corticosterone | GirT | 10 mg/mL in 20% acetic acid | Airbrush, 60 min at RT | Tissue sections of human adrenal glands | [ |
| Carboxylic acid as targeted functional groups | |||||
| Docosahexaenoic acid, arachidonic acid, oleic acid, palmitoleic acid, eicosapentaenoic acid, linoleic acid | PA | 2 mM with 10 mM of activation reagents in ACN | Electrospraying or airbrush | Brain tissue sections from rats | [ |
| 3-Maleylpyruvate, N-acetyl-L-glutamate, palmitic acid, oleic acid, stearic acid and more other metabolites | PA | 6 mM PA and 30 mM activation reagents in ACN | Electrospraying | Leaf and root tissue sections of two different maize genotypes (B73 and Mo17) | [ |
| Fatty acids (C16:1, C16:0, C18:2, C18:1, C18:0, C18:3, C20:4, C20:0, C22:6, C22:4) | DMPI | 3 mM with 1 mM HATU in 80% ACN | Electrospraying | Tumor and normal tissue sections of patients with thyroid carcinoma, brain tissue sections of rat | [ |
| Thiol as targeted functional groups | |||||
| α-Chain and ß-chain of reduced insulin, glutathione, cysteine, cysteinylglycine | CHC-MAL*** | 10 mg/mL in 50% ACN | Automatic spraying | Liver and pancreas tissue sections of pig, tumor tissue sections of mouse xenograft | [ |
| Double bond groups | |||||
| PC 36:1, PS 36:2 isomers | Benzaldehyde | Vapor of benzaldehyde | Custom-made reaction chamber, triggered by 254 nm | Brain tissue sections of C57BL6/N mice | [ |
| PC 34:1, PC 36:1 isomers | BPh* | 20 mg/mL in solution (ACN: isopropanol: H2O, 6:3:1 with 0.5% TFA) | 3 min with UV-light | Brain tissue sections of C57BL6/N mice and tegument of | [ |
| PC 34:1, PC 36:1 isomers | Ozone | Gas | High-pressure linear ion trap with ozone | Brain tissue sections of ND2:SmoA1 transgenic mice containing tumors | [ |
| PC 34:1 isomers | Ozone | Ozone from an ozone generator | Glass flask flushed with the flow of ozone, up to 30 min | Brain tissue sections of BALB/c mice, human colon tissue sections | [ |
CA, 4-hydroxy-3-methoxycinnamaldehyde; NBA, 2-nitrobenzaldehyde; TAHS, p-N,N,N-trimethylammonioanilyl N-hydroxysuccinimidyl carbamate iodide; DPP-TFB, 2,4-diphenyl-pyranylium tetrafluoroborate; DPP, 2,4-diphenyl-pyranylium; PBDPP, 1,4-phenylene-4,4′-bis (2,6-diphenyl-4-pyrylium); TMP, 2,4,6-trimethylpyrylium; FMP-8: 4-(10-bromoanthracen-9-yl)-2-fluoro-1-methylpyridin-1-ium iodide; FMP-9, 4-(anthracen-9-yl)-2-fluoro-1-ethylpyridin-1-ium iodide; FMP-10, 4-(anthracen-9-yl)-2-fluoro-1-methylpyridin-1-ium iodide; FMPTS, 2-fluoro-1-methylpyridinium p-toluenesulfonate; (N-Me)Py+B(OH), 4-(N-methyl)pyridinium boronic acid; DNPH, 2,4-dinitrophenylhydrazine; DMNTH, 4-dimethylamino-6-(4-methoxy-1-naphthyl)-1,3,5-triazine-2-hydrazine; GirT, Girard’s reagent T; PA, 2-picolylamine (PA); DMPI, N,N-dimethylpiperazine iodide; CHC-Mal, (E)-2-cyano-N-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-3-(4-hydroxyphenyl)-acrylamide (CHC-Mal); BPh, benzophenone; ACN, acetonitrile; TFA, trifluoroacetic acid; EtOH, ethanol; FA, formic acid; TEA, triethylamine; RT, room temperature; HATU, 2-(7-azabenzotriazol-1-yl)-N,N,N´,N´-tetramethyluronium hexafluorophosphate; MeOH, methanol
*Reactive matrix; **Reactive matrix in high concentration; ***Reactive matrix for small thiol-containing molecules
Fig. 3OTCD reactions targeting amines
Fig. 4OTCD reactions targeting phenolic hydroxyl groups
Fig. 5OTCD reactions targeting carbonyls
Fig. 6OTCD reactions targeting carboxylic acids
Fig. 7OTCD reactions targeting thiols
Fig. 8OTCD reactions targeting double bonds